Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
# START YOAST BLOCK # --------------------------- User-agent: * Disallow: Sitemap: https://onchillespharma.com/sitemap_index.xml # --------------------------- # END YOAST |
Title | Onchilles Pharma | Neutrophils and |
Description | ABOUT ONCHILLES Developing first-in-class cancer therapeutics with a pathway activated by neutrophils to induce apoptosis in cancer |
Keywords | N/A |
WebSite | onchillespharma.com |
Host IP | 107.180.26.63 |
Location | United States |
Site | Rank |
US$3,390,778
Last updated: 2023-05-10 17:02:15
onchillespharma.com has Semrush global rank of 3,121,497. onchillespharma.com has an estimated worth of US$ 3,390,778, based on its estimated Ads revenue. onchillespharma.com receives approximately 391,244 unique visitors each day. Its web server is located in United States, with IP address 107.180.26.63. According to SiteAdvisor, onchillespharma.com is safe to visit. |
Purchase/Sale Value | US$3,390,778 |
Daily Ads Revenue | US$3,130 |
Monthly Ads Revenue | US$93,899 |
Yearly Ads Revenue | US$1,126,782 |
Daily Unique Visitors | 26,083 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
onchillespharma.com. | A | 7199 | IP: 107.180.26.63 |
onchillespharma.com. | NS | 3600 | NS Record: ns42.domaincontrol.com. |
onchillespharma.com. | NS | 3600 | NS Record: ns41.domaincontrol.com. |
onchillespharma.com. | MX | 600 | MX Record: 0 onchillespharma-com.mail.protection.outlook.com. |
onchillespharma.com. | TXT | 600 | TXT Record: google-site-verification=lajXcG1iHMOO-r-v3Fv0LBDwEH-3YHdqRmY19Gmo06s |
onchillespharma.com. | TXT | 600 | TXT Record: v=verifydomain MS=4657611 |
onchillespharma.com. | TXT | 600 | TXT Record: v=spf1 include:spf.protection.outlook.com -all |
onchillespharma.com. | TXT | 600 | TXT Record: 60EFF69CE8 |
Home Science Therapeutics Team Careers NewsRoom Contact ONCHILLES PHARMA Toggle Menu Revealing Innate Immune Pathways to Build FIRST-IN-CLASS MYELOID-FOCUSED CANCER THERAPEUTICS ABOUT ONCHILLES PHARMA Onchilles Pharma is a global drug discovery and development company that leverages novel neutrophil and macrophage biology to develop the next generation of immunotherapies to treat cancer. These myeloid-focused therapeutics exploit new fundamental pathways of the innate immune system and have the potential for universal anti-cancer activity, independent of genetic mutation. Based on this novel myeloid biology, Onchilles is developing a pipeline of first-in-class biologic drug candidates with the potential to be broadly effective against a wide range of cancers. NOVEL NEUTROPHIL AND MACROPHAGE BIOLOGY EMPOWERS ANTI-TUMOR IMMUNITY Neutrophils and macrophages are among the most abundant white blood cells in the immune system, serving as the first line of defense against infections, |
HTTP/1.1 200 OK Date: Wed, 03 Nov 2021 03:27:32 GMT Server: Apache Vary: User-Agent,Accept-Encoding Upgrade: h2,h2c Connection: Upgrade Last-Modified: Mon, 01 Nov 2021 17:00:36 GMT Accept-Ranges: bytes Content-Length: 64585 Cache-Control: max-age=0, no-cache, no-store, must-revalidate Pragma: no-cache Expires: Mon, 29 Oct 1923 20:30:00 GMT Content-Type: text/html; charset=UTF-8 |
Domain Name: ONCHILLESPHARMA.COM Registry Domain ID: 2175032381_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2020-10-09T12:44:27Z Creation Date: 2017-10-16T17:39:39Z Registry Expiry Date: 2021-10-16T17:39:39Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: ok https://icann.org/epp#ok Name Server: NS41.DOMAINCONTROL.COM Name Server: NS42.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2021-09-28T08:17:43Z <<< |